Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Anne E Duggan Divisions of Public Health and Epidemiology and
Gastroenterology, University of Nottingham, Nottingham NG7 2UH
Correspondence to: R F A
Logan richard.logan{at}nottingham.ac.uk
| |
Abstract |
|---|
|
|
|---|
Objective:
To evaluate the performance of a near
patient test for Helicobacter pylori infection in primary care.
Design:
Validation study performed within a randomised trial of four management strategies for dyspepsia.
Setting:
43 general practices around Nottingham.
Subjects:
394 patients aged 18-70 years presenting
with recent onset dyspepsia.
Main outcome measures:
Results of the FlexSure test
compared with an enzyme linked immunosorbent assay (ELISA; HM-CAP) with
an identical antigen profile and with results of an earlier validation
study in secondary care. Diagnostic yield of patients undergoing
endoscopy on the basis of their FlexSure result compared with those of
patients referred directly for endoscopy.
Results:
When used in primary care FlexSure test had a
sensitivity and specificity of 67% (95% confidence interval 59% to
75%) and 98% (95% to 99%) compared with a sensitivity and specificity of 92% (87% to 97%) and 90% (83% to 97%) when used previously in secondary care. Of the H pylori test and refer
group 14% (28/199) were found to have conditions for which H
pylori eradication was appropriate compared with 23% (39/170) of
the group referred directly for endoscopy.
Conclusions:
When used in primary care the sensitivity of the FlexSure test was significantly poorer than in secondary care.
About a third of patients who would have benefited from H pylori
eradication were not detected. Near patient tests need to be
validated in primary care before they are incorporated into management
policies for dyspepsia.
|
Key messages
|
| |
Introduction |
|---|
|
|
|---|
Prescription of "ulcer healing drugs" for dyspepsia accounts for 10% of prescribing costs in general practice, over £500 million in England and Wales in 1996.1 Eradication of Helicobacter pylori in patients with peptic ulcers offers the prospect of reducing the enormous costs of these drugs, and some guidelines for dyspepsia management recommend testing patients in primary care for H pylori. 2 3
Of the tests for H pylori that might be used in primary
care, near patient tests have obvious attractions in being independent of a laboratory and giving a result quickly enough to guide initial management. Initial reports conflict as to the sensitivity and specificity of such tests,4-8 and there has been little
assessment of their accuracy and performance in primary
care.
9 10
As part of a trial of the management of
dyspepsia in primary care we have used a near patient test in two of
the four management strategies being compared. This paper reports our
experience with one near patient test and compares the diagnostic yield
resulting with that from early endoscopy.
| |
Methods |
|---|
|
|
|---|
Between May 1995 and June 1998, 43 general practices in Nottinghamshire took part in a randomised trial of four strategies for the management of dyspepsia (fig 1). Two strategies involved testing for H pylori with the FlexSure test (SmithKline Diagnostics, San Jose, California). In one, patients with positive results on the FlexSure test were referred for endoscopy and in the other, patients with positive results received eradication treatment without further investigation. In the remaining two strategies, patients were not tested for H pylori but were randomised to early endoscopy or received empiric treatment with a proton pump inhibitor.
|
Patients randomised were between 18 and 70 years old. Dyspepsia was defined as symptoms thought to be arising from the upper gastrointestinal tract and of sufficient severity to justify empiric treatment with an H2 antagonist or proton pump inhibitor. Patients were not eligible for inclusion if they had symptoms suggestive of malignancy, a history of peptic ulcer or reflux oesophagitis diagnosed by endoscopy or barium meal, or previous investigation for dyspepsia within the past five years. Onset of symptoms with treatment with non-steroidal anti-inflammatory drugs or with either eradication treatment for H pylori or more than three prescriptions for acid suppression treatment in the past six months were also criteria for exclusion. After randomisation a 7 ml blood sample was taken. For the two strategies requiring H pylori testing the doctor or practice nurse tested serum from the clotted sample. In practices without centrifuges, operators allowed the sample to stand for at least three hours before completing testing according to the manufacturer's instructions. Our previous hospital study showed that this method enabled sufficient serum to form and had a sensitivity of 92% (95% confidence interval 87% to 97%) and specificity of 90% (83% to 97%).11
After recruitment the completed near patient test card and blood sample
were sent to University Hospital. The serum remaining was stored at
400 C and later tested with an immunoassay
based H pylori test with identical antigen profile ((enzyme
linked immunosorbent assay (ELISA); HM-CAP, Enteric Products, Westbury,
NY, US). Testing was performed by a single operator blinded to the
FlexSure results.
All general practitioners and practice nurses from the highest recruiting practices were sent a questionnaire with a five point Likert scale, asking about the test's ease of performance and interpretation of results.
Results were analysed with SPSS (SPSS, Chicago,
IL, US). Differences in the prevalence of disease between groups was
assessed with a
2 test. Antibody titres of
patients with true positive and false negative FlexSure test results
were compared by using Mann-Whitney U test and the Wilcoxon rank sum
test for non-parametric data. Linear regression and log linear
regression were used to assess the relation between tests performed and
the proportion of false negative results for each operator. The trial
was approved by the University Hospital ethics committee and the local
medical committee for Nottinghamshire.
| |
Results |
|---|
|
|
|---|
Patients and FlexSure test results
Between May 1995 and June 1998, 762 patients were recruited to the
trial. The mean (range) age of patients was 42 (18-73) years. In 27%
(204/762) of patients dyspepsia was of recent onset while in 28% (208)
symptoms had first occurred five or more years earlier. In 422 (56%)
symptoms of dyspepsia were reported to be of sufficient severity to
interfere with the patient's normal daily activities. FlexSure testing
was performed on 394 patients in 39 general practices. Three patients
refused testing. In the four remaining practices no patients were
randomised to the two strategies involving H pylori testing.
On the basis of the near patient test 98 (25%) patients were positive
for H pylori, 291 (73%) were negative for H
pylori, and for five patients (1%) the results were invalid (the
control line failed to appear).
Validation against ELISA
Five patients did not have serum available for ELISA testing. Of
the 389 remaining, 139 (36%) patients had positive results for H
pylori by the ELISA test, 241 (62%) had negative results, and
nine (2%) had indeterminate ELISA results, lying between the positive
and negative cut off. The FlexSure results relative to the ELISA
results are shown in table 1. FlexSure had a sensitivity of 67% (59%
to 75%) and a specificity of 98% (95% to 99%) against ELISA. Eight
of the nine indeterminate results on ELISA were negative on FlexSure
testing. The correlation between ELISA titre and FlexSure result is
shown in figure 2. ELISA titres in the false negative FlexSure group
were significantly lower than in the true positive group
(P<0.0001).
|
|
Performance of the test
Only one practice had a centrifuge. In all other practices blood
specimens were allowed to stand before testing. The mean number of
tests performed in each practice was 21 (range 1-43) with a mean of 8 (range 1-31) being performed by each operator. Practice nurses
performed 74% (292) of tests and general practitioners 17% (66); in
10% (39) of cases the operator was unknown. The invalid results
occurred in five different practices. The mean number of false negative
results per individual operator was 0.8 (range 0-5), and the mean
number of false negatives per practice was 1 (range 0-8). There was no
correlation between the number of tests performed by an operator and
the percentage of false negative results (P=0.8). Nineteen (79%) of
the 24 general practitioners and practice nurses surveyed about the
test replied. Eighteen (95%) respondents reported that the test was
easy to perform and the results easy to interpret. Four (21%)
respondents found it a problem to wait for serum to form, and only two
(11%) believed the patients found it a problem to wait for results.
Patients were usually contacted by phone with the result.
Endoscopic findings in the test and refer versus endoscopy group
Of the 394 patients who underwent the FlexSure test, 199 had been
randomised to the H pylori test and refer strategy. In this
group 52 (26%) patients had a positive result on the FlexSure test; 49 attended for endoscopy and three refused endoscopy. Endoscopic diagnoses in this group are shown in table 2. Eleven of the 12 patients
with duodenal ulcers and the seven patients with erosive duodenitis
were also positive for H pylori on urease testing (CLO test,
Delta West Ply, Bentley, Australia). One patient had a malignant gastric ulcer. Of the 147 patients with a negative result on the FlexSure test, 39 were later referred for endoscopy; one had erosive duodenitis and one had a gastic ulcer, both were positive for H
pylori on urease testing.
|
an absolute difference of 9% (1% to 17%).
| |
Discussion |
|---|
|
|
|---|
Near patient tests for H pylori have provided general practitioners with a quick and easy method of testing. Apart from two small studies, however, the performance of these tests has not been assessed in primary care. 9 10 We have found that the performance of one near patient test, which we had previously found to be satisfactory in secondary care was notably poorer with a much lower sensitivity when used in primary care. The explanation for this change is not entirely clear. None of the operators reported difficulty in interpreting the test results. No association was found between the total number of tests performed by an operator and the proportion of false negative results, although most operators performed fewer than 20 tests. We did find that the H pylori antibody titre in the group with false negative FlexSure test results was significantly lower than in true positive group. This might indicate that antibody titres in our original series of patients in secondary care were higher overall than in primary care, with fewer patients with ELISA titres close to borderline.
The immediate question that arises is whether our findings apply to other near patient tests for H pylori. Only one other test, the Helisal rapid blood test, has been validated in primary care. In secondary care this test was reported to have a sensitivity of 88% and specificity of 91%.6 In contrast, Jones et al obtained a sensitivity of 83% and specificity of 78% in primary care in England,9 while Talley et al found the sensitivity was only 59% and specificity 90%, when used by general practitioners in Australia.10
The impact of the lower sensitivity in our randomised trial seems to
have been considerable as the diagnostic yield of ulcer disease in
patients positive for H pylori in the test and refer group
was only two thirds that of the immediate endoscopy group
a figure
exactly in line with that expected from the reduced sensitivity of the test.
Of the various tests for H pylori available for use in
primary care the main attraction of the near patient tests is that the
results are available rapidly enough to guide initial management. Our
results and those of others, however, show that the current tests are
not sufficiently accurate to be used safely for a strategy of testing
and referring patients positive for H pylori for endoscopy. Whether these tests are suitable to guide a strategy of testing and
treating patients positive for H pylori is debatable.
Symptoms of dyspepsia tend to recur and the uncertainty engendered by
an insensitive test may lead to either increased empiric H
pylori eradication or increased referral for endoscopy, or both.
As a whole therefore the benefit of a rapid result is not sufficient to
compensate for the inaccuracy of the current near patient tests. On the
available evidence the best tests for H pylori in primary care remain either laboratory based serology or a carbon labelled urea
breath test.12
| |
Acknowledgments |
|---|
We thank the Nottingham general practitioners and practice nurses whose considerable efforts in recruiting patients made the trial possible.
Contributors: AED and RFAL designed the study and were responsible for data analysis and writing the paper. CE was responsible for data collection, processing, and analysis. RFAL is the guarantor.
| |
Footnotes |
|---|
Funding: The Nottingham Dyspepsia Management Trial has been funded by the NHS Primary/Secondary Interface R&D Programme, Trent Region R&D, Wyeth-Lederle, and Abbott Laboratories. The near patient tests and ELISAs were provided by SmithKline Diagnostics.
Competing interests: None declared.
| |
References |
|---|
|
|
|---|
| 1. | Office of Health Economics. Compendium of health statistics. 10th ed. London: Office of Health Economics, 1997. |
| 2. | British Society of Gastroenterology. Dyspepsia management guidelines [abstract]. London: British Society of Gastroenterology, 1996. |
| 3. | American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 1998; 114: 579-581[Medline]. |
| 4. | Stone M, Mayberry J, Wicks A, Livsey S, Stevens M. The Helisal test: an assessment of readability and performance [abstract]. Gut 1996; 39: 110. |
| 5. | Peitz U, Tillenburg B, Baumann M. Insufficient validity of a new rapid whole blood test for Helicobacter pylori (HP) infection [abstract]. Gastroenterology 1996; 110: 226. |
| 6. |
Moayyedi P, Carter A, Catto A, Heppell R, Grant P, Axon A.
Validation of a rapid whole blood test for diagnosing Helicobacter pylori.
BMJ
1997;
314:
119 |
| 7. |
Reilly T, Poxon V, Sanders D, Elliott T, Walt R.
Comparison of serum, salivary, and rapid whole blood diagnostic test for Helicobacter pylori and their validation against endoscopy tests.
Gut
1997;
40:
454-458 |
| 8. | Kroser J, Faigel D, Furth E, Metz D. Comparison of rapid office-based serology with formal laboratory-based ELISA testing for diagnosis of Helicobacter pylori gastritis. Dig Dis Sci 1998; 43: 103-108[Medline]. |
| 9. | Jones R, Phillips I, Felix G, Tait C. An evaluation of near-patient testing for Helicobacter pylori in general practice. Aliment Pharmacol Ther 1997; 11: 01-05. |
| 10. | Talley N, Lambert JR, Howell S, Lin HHX, Agreus L. An evaluation of whole blood testing for Helicobacter pylori in general practice. Aliment Pharmacol Ther 1998; 12: 641-645[Medline]. |
| 11. | Duggan A, Logan RPH, Knifton A, Logan RFA. Accuracy of near-patient blood tests for Helicobacter pylori. Lancet 1996; 348: 617[Medline]. |
| 12. |
Churchill RD, Hill PG, Holmes GKT.
Breath test is better than near patient blood tests.
BMJ
1998;
316:
1389 |
(Accepted 19 July 1999)